Literature DB >> 22870489

Diagnosis and treatment of the idiopathic inflammatory myopathies.

David J Gazeley, Mary E Cronin.   

Abstract

The idiopathic inflammatory myopathies (IIMs) are rare disorders with the unifying feature of proximal muscle weakness. These diseases include polymyositis(PM), dermatomyositis (DM) and inclusion body myositis (IBM) as the most common. The diagnosis is based on the finding of weakness on exam, elevated muscles enzymes, characteristic histopathology of muscle biopsies, electromyography abnormalities and rash in DM. Myositis-specific antibodies have been helpful in defining subsets of patients with different responses to treatment and prognosis. The cornerstone of therapy is corticosteroids with the addition of other immunosuppressives in severe or refractory disease or patients with intolerable side effects. IBM is particularly difficult to treat but is more slowly progressive as compared with PM or DM. There is still a great need to find more effective and less-toxic therapies.

Entities:  

Keywords:  dermatomyositis; idiopathic inflammatory myopathies; inclusion body myositis; polymyositis

Year:  2011        PMID: 22870489      PMCID: PMC3383495          DOI: 10.1177/1759720X11415306

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  46 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis.

Authors:  Elisabeth Dion; Patrick Cherin; Christine Payan; Jean-Charles Fournet; Thomas Papo; Thierry Maisonobe; Eric Auberton; Olivier Chosidow; Pierre Godeau; Jean-Charles Piette; Serge Herson; Philippe Grenier
Journal:  J Rheumatol       Date:  2002-09       Impact factor: 4.666

Review 3.  Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features.

Authors:  Sally Cox; Vidya Limaye; Catherine Hill; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Int J Rheum Dis       Date:  2010-05       Impact factor: 2.454

4.  Pathologic skeletal muscle perfusion in patients with myositis: detection with quantitative contrast-enhanced US--initial results.

Authors:  Marc-André Weber; Martin Krix; Uta Jappe; Hagen B Huttner; Marius Hartmann; Uta Meyding-Lamadé; Marco Essig; Christoph Fiehn; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  Radiology       Date:  2005-12-21       Impact factor: 11.105

Review 5.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

6.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

7.  Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis.

Authors:  Albert Selva-O'Callaghan; Josep M Grau; Cristina Gámez-Cenzano; Antonio Vidaller-Palacín; Xavier Martínez-Gómez; Ernesto Trallero-Araguás; Eduard Andía-Navarro; Miquel Vilardell-Tarrés
Journal:  Am J Med       Date:  2010-06       Impact factor: 4.965

Review 8.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

9.  Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.

Authors:  Nizar Chahin; Andrew G Engel
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

Review 10.  Exercise effects in patients with adult idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

View more
  5 in total

Review 1.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

2.  Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report.

Authors:  Shriya Patel; Mohammad Abu-Abaa; Feryal Mousavi
Journal:  Cureus       Date:  2022-08-09

3.  Inclusion body myositis: a case of bilateral extremity weakness.

Authors:  Luke Lam; Stephen Scheper; Natalia Zagorski; Mark Chung; Hiroji Noguchi; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2013-12

4.  Tacrolimus-Induced Remission in Drug Resistant Inflammatory Myopathy: A Case Series.

Authors:  Karina Rotella; Milena Rodriguez Alvarez; Yair Saperstein; Manjeet S Bhamra; Su Zhaz Leon; Alekznder Feoktiztov; Isabel M McFarlane
Journal:  Rheumatology (Sunnyvale)       Date:  2018-05-31

5.  Effect of butylphthalide intervention on experimental autoimmune myositis in guinea pigs.

Authors:  Juan Chen; Jingyang Wang; Jiyan Zhang; Chuanqiang Pu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.